EmpowHER 208NCT07102381
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 15 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 53 → 60 locations
- Minor Trial sites expanded: 44 → 53 locations
- Study completion moved earlier from Aug 1, 2030 to May 2, 2030
- Primary completion date: Jan 1, 2028 to Dec 29, 2027
- Notable Eligibility criteria expanded, about 26 words
- Trial sites expanded: 35 → 44 locations
- Secondary endpoints: details revised at 1 of 11 entries
- Minor Study sites: 33 to 35v13
- Minor Trial sites expanded: 30 → 33 locationsv12
- Notable Eligibility criteria expanded, about 44 words
- Trial sites expanded: 26 → 30 locations
- Secondary endpoints: details revised at 1 of 11 entries
- Minor Trial sites expanded: 21 → 26 locationsv10
- Minor Study sites: 20 to 21v9
- Minor Study sites: 18 to 20v8
- Minor Study sites: 17 to 18v7
- Minor Study sites: 13 to 17v6
- Minor Study sites: 10 to 13v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 2 to 10
- Start date changed from estimate of Sep 1, 2025 to Sep 24, 2025
- Minor Study sites: 0 to 2v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of participants with pCR
Timeframe: Up to 8 months
Secondary (11)
Number of participants with Pathologic response by Residual Cancer Burden (RCB) classification
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Number of Participants Discontinuing Study Treatment Due to TEAEs
Number of participants that completed breast conservation surgery (BCS)
Event Free Survival (EFS)
Show 6 moreShow less
Overall Survival (OS)
Number of participants reporting Symptomatic Adverse Events based on Patient-reported Outcome-Common Terminology Criteria for AEs (PRO-CTCAE)
Number of participants reporting Symptomatic Adverse Events based on European Organisation for Research and Treatment of Cancer (EORTC) Item Library
Percentage of all treated participants reporting overall side-effect bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5)
Serum Concentrations of Zanidatamab
Number of Participants Positive for Anti-drug Antibodies to Zanidatamab
Arms and interventions
Zanidatamab with paclitaxelActive comparator
Zanidatamab in combination with chemotherapy paclitaxel
Zanidatamab with docetaxel and carboplatinActive comparator
Zanidatamab in combination with chemotherapy docetaxel and carboplatin
Trastuzumab and pertuzumab with docetaxel and carboplatinActive comparator
Trastuzumab and pertuzumab in combination with chemotherapy docetaxel and carboplatin
Drugs: Zanidatamab, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab
Sites
60 sites in 4 countries
United States 34, Spain 11, Italy 8, Germany 7